tbuckley/cabot-search huggingface dataset:
High type II error and interpretation inconsistencies when attempting to refute transgenerational epigenetic inheritance
Authors: Carlos Guerrero-Bosagna
Journal: Genome biology (2016)

A recently published article in Genome Biology attempts to refute important aspects of the phenomenon of transgenerational epigenetic inheritance (TEI). An alternative explanation of the data is offered here, showing that TEI is indeed not contradicted. Please see related Correspondence article: www.dx.doi.org/10.1186/s13059-016-0981-5 and related Research article: http://genomebiology.biomedcentral.com/articles/10.1186/s13059-015-0619-z
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Authors: Colin C. Pritchard, Joaquin Mateo, Michael F. Walsh, Navonil De Sarkar, Wassim Abida, Himisha Beltran, Andrea Garofalo, Roman Gulati, Suzanne Carreira, Rosalind Eeles, Olivier Elemento, Mark A. Rubin, Dan Robinson, Robert Lonigro, Maha Hussain, Arul Chinnaiyan, Jake Vinson, Julie Filipenko, Levi Garraway, Mary-Ellen Taplin, Saud AlDubayan, G. Celine Han, Mallory Beightol, Colm Morrissey, Belinda Nghiem, Heather H. Cheng, Bruce Montgomery, Tom Walsh, Silvia Casadei, Michael Berger, Liying Zhang, Ahmet Zehir, Joseph Vijai, Howard I. Scher, Charles Sawyers, Nikolaus Schultz, Philip W. Kantoff, David Solit, Mark Robson, Eliezer M. Van Allen, Kenneth Offit, Johann de Bono, Peter S. Nelson
Journal: New England Journal of Medicine (2016)

Inherited mutations in DNA-repair genes such as BRCA2 are associated with increased risks of lethal prostate cancer. Although the prevalence of germline mutations in DNA-repair genes among men with localized prostate cancer who are unselected for family predisposition is insufficient to warrant routine testing, the frequency of such mutations in patients with metastatic prostate cancer has not been established.
Stem Cell Transplantation for Refractory Crohn Disease
Authors: Richard K. Burt, Milton A. Ruiz, Roberto L. Kaiser
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hypomania and mania after withdrawal of tricyclic antidepressants
Authors: S M Mirin, A F Schatzberg, D E Creasey
Journal: American Journal of Psychiatry (1981)

Seven patients who had been maintained on tricyclic antidepressants developed signs of hypomania or mania shortly (two-seven days) after drug withdrawal. Three patients responded promptly to treatment with neuroleptics. One patient receiving lithium and three others who received no further drug treatment experienced more gradual resolution of symptoms. Tricyclic withdrawal is accompanied by changes in the turnover rate of individual neurotransmitters as well as by shifts in the equilibrium between various transmitter systems. These events may be accompanied by alterations in mood. Although relapse to depression is more common, hypomania or mania may also occur.
Fertility and Early Pregnancy Outcomes Following Conservative Treatment for Cervical Intraepithelial Neoplasia and Early Cervical Cancer
Authors: Maria Kyrgiou, Anita Mitra, Evangelos Paraskevaidis
Journal: JAMA Oncology (2016)

<h3>Clinical Question</h3> Does local conservative treatment for cervical intraepithelial neoplasia and early invasive cervical cancer adversely affect successful conception and early pregnancy outcomes in the first and second trimester (&lt;24 weeks of gestation)? <h3>Clinical Application</h3> Local cervical treatment does not adversely affect fertility or first trimester miscarriage, although it is associated with a significant increase in the risk of second trimester miscarriages.
Adoptive Transfer of T-Cell-Receptor Engineered Human T Cells Specifically Reduces Viral Titers in HLA-Transgenic NSG Mice Infected with a Humanized Cytomegalovirus
Authors: Simone Thomas, Niels Lemmermann, Sebastian Klobuch, Jürgen Podlech, Matthias Theobald, Matthias J Reddehase, Wolfgang Herr
Journal: Blood (2014)
Chronic GVHD Is Not Increased with the Use of PBSC Instead of Bone Marrow for T-Replete HLA-Haploidentical Transplanation Using Post-Transplant Cyclophosphamide : A Multivartiate Analysis of 116 Consecutive Transplants from a Single Center
Authors: Asad Bashey, Xu Zhang, Stacey Brown, Katelin Connor, Lawrence E. Morris, H. Kent Holland, Ridgeway Michelle, Scott R. Solomon
Journal: Blood (2014)
An open label, randomised cross-over bioavailability study of oral paclitaxel (oraxol) compared to intravenous paclitaxel 80mg/m<sup>2</sup>.
Authors: Christopher G. C. A. Jackson, Katherine Francis Bayston, Blair Richard McLaren, Louise Bremer, Karen Eden, Min-Fun Rudolf Kwan, Douglas Kramer, Wing Kai Chan, Noelyn Anne Hung, Tak Hung
Journal: Journal of Clinical Oncology (2016)

2569 Background: Paclitaxel has poor oral bioavailability due to the active excretion by p-glycoprotein (Pgp) present on intestinal epithelial cells. Oraxol (Kinex) is a combination of oral paclitaxel and HM30181, a novel, orally administered, non-absorbed specific inhibitor of intestinal Pgp. Oral paclitaxel would avoid the need for IV injections, avoid severe anaphylactic reactions and the side-effects of steroid pre-medication, cost savings and greater patient convenience. We report the absolute bioavailability of Oraxol compared to IV paclitaxel. Methods: We conducted an open label, randomized cross-over pharmacokinetic (PK) study to determine the bioavailability (PK, AUC) and safety of escalating doses of Oraxol over 2 days compared to IV paclitaxel 80mg/m2 over 1 hour in patients with incurable cancer receiving weekly paclitaxel. Following written informed consent, patients were randomized to receive either Oraxol followed one week later by IV paclitaxel or the reverse sequence. Six patients (4 F 2 M) received two daily doses of 270mg. Following review of safety and PK results, two patients were treated with Oraxol 274mg/m2 x 2 days, and then two patients received 313mg/m2 x 2 days. Results: Oraxol was well tolerated with no grade 3/4 drug toxicities at any of the dose levels. AUC0-∞ and Cmax increased with increasing Oraxol dose from 270mg to 274mg/m2 but not with dose escalation to 313mg/m2. Conclusions: Oraxol 615 mg/m2 over 2 days achieved paclitaxel AUC comparable to IV paclitaxel 80 mg/m2. Oraxol safety profile was acceptable without grade 3-4 toxicities. Oraxol represents an ideal drug candidate to replace IV paclitaxel. Clinical trial information: 12614000365662.Oraxol concentration normalised to 615 mg/m2 compared to IV paclitaxel 80 mg/m2 for all subjects. Oraxol Paclitaxel IV AUC0- ¥ (ng.hr/ml) 8638.80±8155.07 (3074.24 – 29773.62) 6824.85±3181.03 (4039.04 – 13862.91) AUC0-t (ng.hr/ml) 6336.42±3408.91 (2928.44 – 12566.67) 6289.23±2397.61 (3911.52 – 10531.10) Cmax0-24 (ng/ml) 572.59±301.88 (330.37 – 1122.34) Cmax24-48 (ng/ml) 448.15±229.01 (292.74 – 913.91) Cmax (ng/ml) 2492.47±362.46 (2025.67 – 3127.89) T1/2 (hr) 48.78±30.76 (21.31 – 128.32) 21.85±8.17 (11.38 – 42.04)
Adaptive Servo-Ventilation for Central Sleep Apnea in Heart Failure.
Authors: Yasuki Kihara, Yoshihiko Seino, Shin-ichi Momomura, Savior-C investigators
Journal: New England Journal of Medicine (2016)

To the Editor: Cowie et al. (Sept. 17 issue)1 report on the results of the Treatment of SleepDisordered Breathing with Predominant Central Sleep Apnea by Adaptive Servo Ventilation in Patients with Heart Failure (SERVE-HF) trial. They found increases in all-cause and cardiovascular mortality among patients with heart failure who received adaptive servo-ventilation therapy, and the adaptive servo-ventilation group had no improvement in quality-of-life measures. These results contradict those of our Study of the Effects of Adaptive Servo-ventilation Therapy on Cardiac Function and Remodeling in Patients with Chronic Heart Failure (SAVIOR-C).2 The majority of patients who received adaptive servoventilation in our study had improvements in quality of life, and the improvement from New York Heart Association (NYHA) functional class III heart failure to class II heart failure was significant. We found that the adaptive servo-ventilation settings differed between the two studies. Cowie et al. manually increased the expiratory and inspiratory positive airway pressures from the default levels to suppress sleep apnea.1 Because the effects of positive airway pressure on cardiac output depend on the baseline pulmonary-capillary wedge pressure,3 we were concerned that excessive increases in levels of airway pressure might diminish cardiac output and induce reflex sympathetic hyperactivity in some patients with mild pulmonary congestion. For this reason, the levels of airway pressure in patients in the SAVIOR-C were maintained at or below the default levels.2,4 It would be useful to know whether high-pressure adaptive servo-ventilation settings precipitated adverse events in their patients. Yasuki Kihara, M.D., Ph.D.
Will neurobiology influence psychoanalysis?
Authors: A M Cooper
Journal: American Journal of Psychiatry (1985)

Neurobiologic research has begun to elucidate brain mechanisms of affective states and behavioral patterns. Discussions of anxiety and sexual identity demonstrate how these researches lead the psychoanalyst to broader views of behaviors that were previously considered entirely psychological in origin. While introspection and extrospection are distinct realms of investigation and conceptualization, they share common boundaries and areas of interpenetration. Psychoanalytic theory is challenged to accord with newer findings in biology and to provide important questions for further research. Neurobiologic advances will continue a centuries-old process of confining the realm of psyche, but there is no danger that mind will disappear.
ATCT-30HYPERGLYCEMIA INDUCED BY PASIREOTIDE IN PATIENTS WITH CUSHING'S DISEASE OR ACROMEGALY
Authors: Julie Silverstein
Journal: Neuro-Oncology (2015)

BACKGROUND: Cushing's disease (CD) and acromegaly are characterized by excessive hormone production by secreting pituitary tumors, resulting in comorbidities such as impaired glucose metabolism. Pasireotide is a next-generation, multireceptor-targeted somatostatin analog approved for treatment of CD (subcutaneous [SC] injection) and acromegaly (long-acting release [LAR] formulation). In clinical studies of pasireotide, hyperglycemia-related adverse events (AEs) were frequently observed. However, differences in reported rates of hyperglycemia among various trials in CD and acromegaly were noted. Here, we review the incidence and highlight differences of pasireotide-induced hyperglycemia in CD and acromegaly. METHODS: We reviewed clinical trials evaluating pasireotide in patients with CD or acromegaly. RESULTS: The frequency of hyperglycemia-related AEs was lower in patients with acromegaly treated with pasireotide LAR (57.3%–67.0%) than in patients with CD treated with pasireotide SC (73.0%). Fewer patients with acromegaly treated with pasireotide LAR discontinued due to hyperglycemia-related AEs, as reported in 2 separate trials (C2305, 3.4%; C2402, 3.8%) and an interim analysis (ACCESS, 0%), than in patients with CD treated with pasireotide SC (6.0%). Hyperglycemia-related AEs occurred in 40.0% of patients with acromegaly treated with pasireotide SC, and 10.0% discontinued treatment because of hyperglycemia. CONCLUSIONS: In studies of pasireotide, the frequency of hyperglycemia-related AEs was lower in acromegaly trials than in the CD trial, regardless of drug formulation, suggesting that disease pathophysiology may play an important role in glucose metabolism. However, among patients with acromegaly, the SC formulation resulted in fewer hyperglycemia-related AEs, indicating that drug formulation may also affect glucose metabolism. Because the CD trial occurred before the acromegaly trials, the benefit of increased physician experience with pasireotide use should also be considered. Ongoing studies evaluating pasireotide LAR in patients with CD and management of pasireotide-induced hyperglycemia in patients with CD or acromegaly (ClinicalTrials.gov identifiers: NCT01374906 and NCT02060383, respectively) will address these key safety issues.
PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma
Authors: Hiroaki Miyoshi, Junichi Kiyasu, Takeharu Kato, Noriaki Yoshida, Joji Shimono, Shintaro Yokoyama, Hiroaki Taniguchi, Yuya Sasaki, Daisuke Kurita, Keisuke Kawamoto, Koji Kato, Yoshitaka Imaizumi, Masao Seto, Koichi Ohshima
Journal: Blood (2016)
Grief
Authors: Sarah Ringold
Journal: JAMA (2005)

GriefG rief (bereavement) is the emotional and physical response to the death of a loved one.Grief is associated with a wide range of emotions, including sadness, anger, guilt, and despair.Each individual may experience a different set of specific emotions, but, in general, these emotions diminish as time passes and with support from family and friends.The June 1, 2005, issue of JAMA includes an article evaluating a new type of psychotherapy (talk therapy) developed specifically to treat people with complicated grief.
Case 48-1986
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, Gustave A. Laurenzi, Eugene J. Mark
Journal: New England Journal of Medicine (1986)

Presentation of CaseA 20-year-old woman was admitted to the hospital because of systemic lupus erythematosus and respiratory distress.The patient was a native of Cambodia and had resided temporarily in Thailand. There was a history of hepatitis at the age of 12 years. Seven years before admission she had had repeated bouts of fever that were believed to be secondary to malaria. Four years before entry she immigrated to this country, where a tuberculin skin test was found to be positive. An x-ray study of the chest was reported to be negative for active pulmonary disease, and isoniazid was . . .
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
Authors: Valeria Santini, Antonio Almeida, Aristoteles Giagounidis, Stefanie Gröpper, Anna Jonasova, Norbert Vey, Ghulam J. Mufti, Rena Buckstein, Moshe Mittelman, Uwe Platzbecker, Ofer Shpilberg, Ron Ram, Consuelo del Cañizo, Norbert Gattermann, Keiya Ozawa, Alberto Risueño, Kyle J. MacBeth, Jianhua Zhong, Francis Séguy, Albert Hoenekopp, C.L. Beach, Pierre Fenaux
Journal: Journal of Clinical Oncology (2016)

This international phase III, randomized, placebo-controlled, double-blind study assessed the efficacy and safety of lenalidomide in RBC transfusion-dependent patients with International Prognostic Scoring System lower-risk non-del(5q) myelodysplastic syndromes ineligible for or refractory to erythropoiesis-stimulating agents.In total, 239 patients were randomly assigned (2:1) to treatment with lenalidomide (n = 160) or placebo (n = 79) once per day (on 28-day cycles). The primary end point was the rate of RBC transfusion independence (TI) ≥ 8 weeks. Secondary end points were RBC-TI ≥ 24 weeks, duration of RBC-TI, erythroid response, health-related quality of life (HRQoL), and safety.RBC-TI ≥ 8 weeks was achieved in 26.9% and 2.5% of patients in the lenalidomide and placebo groups, respectively (P < .001). Ninety percent of patients achieving RBC-TI responded within 16 weeks of treatment. Median duration of RBC-TI with lenalidomide was 30.9 weeks (95% CI, 20.7 to 59.1). Transfusion reduction of ≥ 4 units packed RBCs, on the basis of a 112-day assessment, was 21.8% in the lenalidomide group and 0% in the placebo group. Higher response rates were observed in patients with lower baseline endogenous erythropoietin ≤ 500 mU/mL (34.0% v 15.5% for > 500 mU/mL). At week 12, mean changes in HRQoL scores from baseline did not differ significantly between treatment groups, which suggests that lenalidomide did not adversely affect HRQoL. Achievement of RBC-TI ≥ 8 weeks was associated with significant improvements in HRQoL (P < .01). The most common treatment-emergent adverse events were neutropenia and thrombocytopenia.Lenalidomide yields sustained RBC-TI in 26.9% of RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes ineligible for or refractory to erythropoiesis-stimulating agents. Response to lenalidomide was associated with improved HRQoL. Treatment-emergent adverse event data were consistent with the known safety profile of lenalidomide.
Abnormal Seroresponse to Common Viruses in CLL RAI0
Authors: Silvia de Sanjosé, Claudia Robles, Tim Waterboer, Delphine Casabonne, Angelika Michel, Yolanda Benavente, Laura Costas, Eva Gonzalez-Barca, Marta Aymerich, Elias Campo, Adonina Tardon, Paloma Garcia Sanmartin, Gemma Castaño-Vinyals, Trinidad Dierssen-Sotos, Nuria Aragones, Marina Pollan, Manolis Kogevinas, Michael Pawlita
Journal: Blood (2014)
P-069 Neoadjuvant chemotherapy for esophageal cancer: comparison of DCS (DTX/CDDP/S-1) chemotherapy with FAN (5-FU/ADM/Nedaplatin) chemotherapy
Authors: H. Shimoji, T. Nishimaki, H. Karimata, K. Hayasaka
Journal: Annals of Oncology (2016)
Successful use of Hemospray as a bridge to surgery in life-threatening bleeding from a gastrointestinal stromal tumor of the stomach
Authors: Giovanna Venezia, Giuliano Asnaghi, Aldo Manca, Luigi Ghezzo
Journal: Endoscopy (2016)

A 68-year-old man who was taking acetylsalicylic acid for a previous right occipital stroke was admitted to our hospital for an episode of syncope with subsequent facial trauma and mandibular fracture. The syncopal episode was due to hemorrhagic shock resulting from a massive hematemesis. His initial laboratory data showed the following: hemoglobin level 5.4 g/dL, white blood cell count (WBC) 17 620/mm3 with a normal differential, platelets 118 000/mm3, blood urea nitrogen 82 mg/dL, creatinine 1.3 mg/dL, international normalized ratio (INR) 1.28, and he had an admission Rockall score of 6 and a Glasgow Blatchford Score (GBS) of 18.
Prostate Cancer
Authors: James A. Talcott
Journal: Annals of Internal Medicine (2015)

This issue provides a clinical overview of prostate cancer, focusing on prevention, screening, diagnosis, staging, shared decision making, consultation,, the role of primary care providers, and treatment. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic in collaboration with the ACP's Medical Education and Publishing divisions and with the assistance of additional science writers and physician writers.
Reasons for the sharp increase of genital chlamydia infections reported in the first months of 2007 in Sweden
Authors: I Velicko, S Kühlmann-Berenzon, A Blaxhult
Journal: Eurosurveillance (2007)

After a continuous increase in the reported chlamydia incidence over the past 10 years in Sweden, the incidence decreased by 2% in 2006. A new genetic variant of Chlamydia trachomatis (nvCT) was discovered in Sweden in October 2006 that could not be detected by some of the commonly used diagnostic tests, which led to underreporting of chlamydia cases. This variant has also been called "swCT" by some authors. After the switch at the end of 2006 to other diagnostic tests that can detect nvCT, the reported incidence rose considerably (75 per 100,000 population) in the beginning of 2007. The objective of this study was to explore alternative explanations for this increase and to propose further action if needed. A data quality check was done in order to exclude double reporting and delayed reporting. To compare the incidence of chlamydia and the proportion of the population that was tested, we divided the Swedish counties into two groups, according to the diagnostic test used. We estimated the chlamydia incidence trend for January and February in the years from 2000 to 2005 by regression model, and predict the chlamydia incidence for the same period in 2006 and 2007. The age and sex distribution of the cases in January and February did not differ between the years 2000 to 2007. The proportion of tested people increased on average by 5% every year. If we assume that the percentage of the population that was tested had been 20% higher in 2007 than in 2006, the incidence predicted by the model for January and February 2007 is exactly the same as the incidence that was actually observed. The change of diagnostic test and an increase in the number of people tested, as well as the increase in the prevalence of CT have probably all contributed to the increased numbers of reported chlamydia cases in January and February 2007. These findings support the need for enhanced prevention campaigns in order to control spread of CT.
Hierarchical Fabrication of Engineered Vascularized Bone Biphasic Constructs via Dual 3D Bioprinting: Integrating Regional Bioactive Factors into Architectural Design
Authors: Haitao Cui, Wei Zhu, Margaret Nowicki, Xuan Zhou, Ali Khademhosseini, Lijie Grace Zhang
Journal: Advanced Healthcare Materials (2016)

A biphasic artificial vascularized bone construct with regional bioactive factors is presented using dual 3D bioprinting platform technique, thereby forming a large functional bone grafts with organized vascular networks. Biocompatible mussel-inspired chemistry and "thiol-ene" click reaction are used to regionally immobilize bioactive factors during construct fabrication for modulating or improving cellular events. As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Case 17-1972
Authors: Richard C. Cabot, Benjamin Castleman, Robert E. Scully, Betty U. McNeely, Rita M. Kelley
Journal: New England Journal of Medicine (1972)

Presentation of CaseA 19-year-old girl was admitted to the hospital because of paraplegia.At the age of three years a palpable left axillary lymph node was found, and subsequently there was enlargement of left cervical lymph nodes. An x-ray film of the chest (Fig. 1) revealed a large mass in the left posterior mediastinum that eroded several ribs posteriorly and contained extensive stippled calcification. Biopsy of the left axillary lymph node disclosed a ganglioneuroblastoma. Radiation treatment in a dose of 2000 R was delivered to the tumor and to the left side of the neck, and chloroquine mustard was . . .